United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices
Summary
GlobalData’s new report, United States Drug Delivery Devices Market Outlook to 2023, provides key market data on the United States Drug Delivery Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories - Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
- Market size and company share data for Drug Delivery Devices market categories - Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
- Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
- 2016 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the United States Drug Delivery Devices market.
- Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc, Hospira Inc, Becton Dickinson and Co, Boehringer Ingelheim GmbH, Baxter International Inc, Medtronic plc and others.
Reasons to buy- Develop business strategies by identifying the key market categories poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
- 1 Table of Contents 2
- 1.1 List of Tables 4
- 1.2 List of Figures 8
- 2 Introduction 9
- 2.1 What Is This Report About? 9
- 2.2 Drug Delivery Devices Market Segmentation 9
- 2.3 Definitions of Markets Covered in the Report 10
- 3 Drug Delivery Devices Market, United States 13
- 3.1 Drug Delivery Devices Market, United States, Revenue ($m), 2009-2023 13
- 3.2 Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016 15
- 3.3 Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016 16
- 3.4 Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 17
- 3.5 Drug Delivery Devices Market, United States, Revenue ($m), 2009-2016 19
- 3.6 Drug Delivery Devices Market, United States, Revenue ($m), 2016-2023 21
- 3.7 Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 23
- 3.8 Drug Delivery Devices Market, United States, Volume (Units), 2009-2016 25
- 3.9 Drug Delivery Devices Market, United States, Volume (Units), 2016-2023 27
- 3.10 Drug Delivery Devices Market, United States, Company Share by Revenue ($m), 2016 29
- 4 Central Venous Catheters Market, United States 31
- 4.1 Central Venous Catheters Market, United States, Revenue Mix ($m), 2016 31
- 4.2 Central Venous Catheters Market, United States, Segment Contribution (%), 2016 32
- 4.3 Central Venous Catheters Market, United States, Revenue ($m), 2009-2016 33
- 4.4 Central Venous Catheters Market, United States, Revenue ($m), 2016-2023 35
- 4.5 Central Venous Catheters Market, United States, Volume (Units), 2009-2016 37
- 4.6 Central Venous Catheters Market, United States, Volume (Units), 2016-2023 39
- 4.7 Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), 2015-2016 41
- 4.8 Central Venous Catheters Market, United States, Company Share by Revenue ($m), 2016 42
- 5 Infusion Systems Market, United States 44
- 5.1 Infusion Systems Market, United States, Revenue Mix ($m), 2016 44
- 5.2 Infusion Systems Market, United States, Segment Contribution (%), 2016 45
- 5.3 Infusion Systems Market, United States, Revenue ($m), 2009-2016 46
- 5.4 Infusion Systems Market, United States, Revenue ($m), 2016-2023 48
- 5.5 Infusion Systems Market, United States, Volume (Units), 2009-2016 58
- 5.6 Infusion Systems Market, United States, Volume (Units), 2016-2023 60
- 5.7 Infusion Systems Market, United States, Distribution Share by Revenue ($m), 2015-2016 70
- 5.8 Infusion Systems Market, United States, Company Share by Revenue ($m), 2016 71
- 6 Needle Free Injections Market, United States 73
- 6.1 Needle Free Injections Market, United States, Revenue ($m), 2009-2016 73
- 6.2 Needle Free Injections Market, United States, Revenue ($m), 2016-2023 74
- 6.3 Needle Free Injections Market, United States, Volume (Units), 2009-2016 75
- 6.4 Needle Free Injections Market, United States, Volume (Units), 2016-2023 76
- 6.5 Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016 77
- 6.6 Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016 78
- 7 Metered Dose Inhaler Devices Market, United States 80
- 7.1 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2009-2016 80
- 7.2 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2016-2023 81
- 7.3 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2009-2016 82
- 7.4 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2016-2023 83
- 7.5 Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), 2015-2016 84
- 7.6 Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), 2016 85
- 8 Overview of Key Companies in United States, Drug Delivery Devices Market 87
- 8.1 GlaxoSmithKline Plc 87
- 8.2 Teleflex Inc 87
- 8.3 AstraZeneca Plc 87
- 8.4 C. R. Bard Inc 88
- 8.5 Hospira Inc 88
- 8.6 Becton Dickinson and Co 88
- 8.7 Edwards Lifesciences Corp 88
- 8.8 Baxter International Inc 89
- 8.9 Boehringer Ingelheim GmbH 89
- 8.10 Medtronic Plc 89
- 8.11 Smiths Medical 90
- 8.12 B. Braun Melsungen AG 90
- 8.13 Pfizer Inc 90
- 8.14 Fresenius Kabi AG 91
- 8.15 Merck & Co Inc 91
- 9 Drug Delivery Devices Market Pipeline Products 92
- 10 Financial Deals Landscape 98
- 10.1 Acquisition 98
- 10.2 Asset Transactions 105
- 10.3 Debt Offerings 107
- 10.4 Equity Offerings 147
- 10.5 Merger 223
- 10.6 Partnerships 225
- 10.7 Private Equity 252
- 10.8 Venture Financing 256
- 11 Recent Developments 285
- 11.1 Corporate Communications 285
- 11.2 Financial Announcements 418
- 11.3 Government and Public Interest 875
- 11.4 Legal And Regulatory 881
- 11.5 Other Significant Developments 896
- 11.6 Product News 919
- 11.7 Strategy And Business Planning 942
- 12 Appendix 954
- 12.1 Research Methodology 955
- 12.2 GlobalData Consulting 957
- 12.3 Contact Us 958
- 12.4 Disclaimer 958
- 1.1 List of Tables
- Table 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023 36
- Table 2: Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016 38
- Table 3: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 40
- Table 4: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 42
- Table 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 44
- Table 6: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 46
- Table 7: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016 48
- Table 8: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023 50
- Table 9: Drug Delivery Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016 52
- Table 10: Central Venous Catheters Market, United States, Segment Contribution (%), 2016 54
- Table 11: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 56
- Table 12: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 58
- Table 13: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 60
- Table 14: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 62
- Table 15: Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 63
- Table 16: Central Venous Catheters Market, United States, Company Share by Revenue ($m), USD Constant, 2016 65
- Table 17: Infusion Systems Market, United States, Segment Contribution (%), 2016 67
- Table 18: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 69
- Table 19: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 71
- Table 20: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 73
- Table 21: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 75
- Table 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 77
- Table 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 79
- Table 24: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016 81
- Table 25: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023 83
- Table 26: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016 85
- Table 27: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016 87
- Table 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023 89
- Table 29: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023 91
- Table 30: Infusion Systems Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 92
- Table 31: Infusion Systems Market, United States, Company Share by Revenue ($m), USD Constant, 2016 94
- Table 32: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 95
- Table 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 96
- Table 34: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 97
- Table 35: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 98
- Table 36: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 99
- Table 37: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016 101
- Table 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 102
- Table 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 103
- Table 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 104
- Table 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 105
- Table 42: Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 106
- Table 43: Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016 108
- Table 44: Drug Delivery Devices Market Pipeline Products 114
- Table 45: Peaceful Union Acquires Sharklet Technologies 120
- Table 46: Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million 121
- Table 47: Becton, Dickinson to Acquire C. R. Bard for USD24 Billion 122
- Table 48: Shire May Acquire Radius Health 124
- Table 49: PixarBio Terminates Acquisition of InVivo Therapeutics for USD77 Million 125
- Table 50: Merck and Allergan May Acquire Biogen 126
- Table 51: ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 127
- Table 52: PAVmed Raises USD5 Million in Private Placement of Notes and Warrants 129
- Table 53: Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 130
- Table 54: Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 131
- Table 55: Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 132
- Table 56: Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 133
- Table 57: Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 134
- Table 58: Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 135
- Table 59: Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 136
- Table 60: Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 137
- Table 61: Skinvisible Raises USD0.2 Million in Issue of 10% Convertible Promissory Notes Due 2018 138
- Table 62: Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 139
- Table 63: Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 141
- Table 64: Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 143
- Table 65: Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 145
- Table 66: Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 147
- Table 67: Premier Biomedical Raises Funds in Third Tranche of Private Placement of 10% Notes Due 2016 149
- Table 68: Catalent Prices Private Placement of 4.75% Notes Due 2024 for USD404.5 Million 150
- Table 69: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 151
- Table 70: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 153
- Table 71: Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 155
- Table 72: Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 157
- Table 73: Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 159
- Table 74: Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 161
- Table 75: Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 163
- Table 76: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 165
- Table 77: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 167
- Table 78: KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares 169
- Table 79: Clearside Biomedical Plans to Raise up to USD50 Million in Public Offering of Shares 170
- Table 80: Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares 171
- Table 81: MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 172
- Table 82: PhaseRx Plans to Raise up to USD15 Million in Public Offering of Shares and Warrants 173
- Table 83: EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 174
- Table 84: Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering 176
- Table 85: Savara Raises USD42.9 Million in Public Offering of Shares 177
- Table 86: Premier Biomedical to Raise Funds through Public Offering of Shares 179
- Table 87: MRI Interventions Raises USD13.3 Million in Private Placement of Units 180
- Table 88: Alnylam Pharma Prices Public Offering of Shares for USD359.4 Million 181
- Table 89: Corium International Raises USD40.3 Million in Public Offering of Shares 183
- Table 90: Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 185
- Table 91: Bellerophon Therapeutics to Raise USD30 Million in Private Placement of Shares 187
- Table 92: Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 188
- Table 93: Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 190
- Table 94: Savara to Raise up to USD18 Million in Public Offering of Shares 192
- Table 95: BioPharmX Raises USD5 Million in Private Placement of Shares and Warrants 193
- Table 96: NanoCarrier Agrees to Invest in Tocagen 194
- Table 97: Capnia Files Registration Statement for Secondary Offering of Shares 195
- Table 98: Adamis Pharma Raises USD17.3 Million in Public Offering of Shares 196
- Table 99: AngioDynamics Prices Public Offering of Shares for USD38 Million 198
- Table 100: Tocagen Raises USD97.8 Million in IPO 199
- Table 101: Premier Biomedical Raises USD0.3 Million in First Tranche of Private Placement of Shares and Warrants 201
- Table 102: Catalyst Biosciences Raises USD20.7 Million in Public Offering of Units 202
- Table 103: Alliqua BioMedical Raises USD2.8 Million in Private Placement of Shares 204
- Table 104: Evoke Pharma Raises USD8 Million in Public Offering of Shares 205
- Table 105: Windtree Therapeutics Raises USD10.5 Million in Private Placement of Units 207
- Table 106: pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 209
- Table 107: Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants 210
- Table 108: Valeritas Files Registration Statement for IPO for up to USD50 Million 212
- Table 109: PAVmed to Raise USD10.4 Million in Private Placement of Shares upon Exercise of Warrants 214
- Table 110: Premier Biomedical Withdraws Public Offering of Shares 215
- Table 111: PAVmed Raises Additional Funds in Second and Final Tranche of Private Placement of Units 216
- Table 112: Corium International Raises USD20 Million in Public Offering of Shares 217
- Table 113: Nu-Med Plus Raises USD0.3 Million in Private Placement of Shares 218
- Table 114: Capnia Raises USD2 Million in First Tranche of Private Placement of Shares 219
- Table 115: PAVmed Raises USD1.5 Million in First Tranche of Private Placement of Units 220
- Table 116: Zynerba Pharma Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 221
- Table 117: Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 223
- Table 118: Braeburn Pharma to Raise USD40 Million in Private Placement of Shares 225
- Table 119: Capnia Raises USD10 Million in Private Placement of Shares 226
- Table 120: Milestone Scientific Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering of Shares 227
- Table 121: AngioDynamics Prices Public Offering of Shares for USD32 Million 229
- Table 122: PAVmed to Raise USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 231
- Table 123: ConvaTec Raises USD1.8 Billion in IPO 232
- Table 124: Galena Biopharma to Raise Funds in Public Offering of Shares 233
- Table 125: BioPharmX Raises USD12.5 Million in Public Offering of Units and Warrants 234
- Table 126: Delcath Systems Prices Public Offering Shares and Warrants for USD1.3 Million 236
- Table 127: T2 Biosystems Raises USD40 Million in Private Placement of Shares 237
- Table 128: Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 238
- Table 129: Catalent to Raise Funds through Public Offering of Shares 239
- Table 130: MRI Interventions to Raise USD4.3 Million in Private Placement of Units 240
- Table 131: BioMarin Pharma Prices Public Offering of Shares for USD720 Million 241
- Table 132: Osprey Medical to Raise USD0.8 Million in Share Purchase Plan of CDIs 242
- Table 133: Adamis Pharma to Raise USD11 Million in Private Placement of Units 243
- Table 134: Dipexium Pharma Merges with PLx Pharma 245
- Table 135: Infuseon Therapeutics Enters into Agreement with Oncosynergy 247
- Table 136: Nobilis Therapeutics Enters into Agreement with Submersible Systems 248
- Table 137: MannKind and One Drop to Enter into Agreement 249
- Table 138: TWi Pharma Enters into Agreement with Intech Biopharm 250
- Table 139: United Therapeutics Enters into Licensing Agreement with Respira Therapeutics 251
- Table 140: Audax Medical Enters into Licensing Agreement with Northeastern University 252
- Table 141: CannaRoyalty Enters into Licensing Agreement with NuTrae 253
- Table 142: ViaCyte Enters into Research Agreement with W. L. Gore & Associates 254
- Table 143: OncoSec Medical Enters into Agreement with Inhibrx 255
- Table 144: Northwell Health Enters into Partnership with United Therapeutics 256
- Table 145: PharmaJet Enters into Agreement with Serum Institute of India 257
- Table 146: Aequus Pharma to Enter into Licensing Agreement with Transdermal Research Pharm Labs 258
- Table 147: Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 259
- Table 148: Hikma Pharma Enters into Licensing Agreement with Orion 261
- Table 149: A1 Group Enters into Licensing and Distribution Agreement ?with Novaceutical Sciences 262
- Table 150: 3M Drug Delivery Systems Partners with Panacea Pharma 263
- Table 151: Neuronex Enters Into Licensing Agreement With SK Biopharmaceuticals For DZNS Technology 264
- Table 152: Pfizer Terminates its Licensing Agreement with pSivida 265
- Table 153: Iatric Systems Enters into Agreement with Hospira 266
- Table 154: Tepha Enters into Agreement with Metabolix 267
- Table 155: Bayer Enters into Licensing Agreement with DelSiTech 268
- Table 156: ALZYN Enters into Licensing Agreement with Transdermal Delivery Solutions 269
- Table 157: Themis Medicare Enters into Agreement with Nevakar 270
- Table 158: Qualcomm Partners with Boehringer Ingelheim Pharma 271
- Table 159: SkinJect Enters into Licensing Agreement with University of Pittsburgh 272
- Table 160: BioCorRx Enters into Licensing Agreement with Therakine 273
- Table 161: 3i Group to Invest USD136 Million in Cirtec Medical Systems from Century Park Capital Partners 274
- Table 162: AGIC Capital to Acquire Ritedose From Olympus Partners 275
- Table 163: 410 Medical Raises USD3.3 Million in Series A Financing 276
- Table 164: Mentor Capital Invests USD1 Million in GW Pharma 277
- Table 165: Otomagnetics Raises USD0.3 Million in Venture Financing 278
- Table 166: Pharmajet Raises USD3 Million in Venture Financing 279
- Table 167: 410 Medical Raises Additional USD2.1 Million in Series A Financing 280
- Table 168: NexGen Medical Systems Raises USD1.5 Million in Venture Financing 281
- Table 169: Xeris Pharma Raises Additional USD30 Million in Series C Financing 282
- Table 170: Respira Therapeutics to Raise Funds through Series B Preferred Stock Financing 284
- Table 171: Ivenix Raises USD50 Million in First Tranche of Equity Financing 285
- Table 172: Ivenix Raises USD10 Million in Venture Financing 286
- Table 173: Surefire Medical Raises USD12.8 Million in First Round of Series D Financing 287
- Table 174: Unilife Raises USD5 Million in Venture Financing 288
- Table 175: iVeena Delivery Systems to Raise USD1 Million in Venture Financing 289
- Table 176: NapaJen Pharma to Raise Funds in Equity Financing 290
- Table 177: Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing 291
- Table 178: Tocagen Raises USD2.73 Million in Venture Financing 292
- Table 179: Impel NeuroPharma Raises USD22.3 Million in Venture Financing 293
- Table 180: Unilife Raises USD10.6 Million in Financing Round 294
- Table 181: Propeller Health Raises USD21.5 Million in Series C Financing 295
- Table 182: BioQ Pharma Raises USD15 Million in Financing Round 296
- Table 183: Enable Injections Raises USD30 Million in Series A Financing 297
- Table 184: QuiO Technologies Raises USD1.05 Million in Seed Financing 299
- Table 185: Impel NeuroPharma Raises USD0.08 Million in Venture Financing 300
- Table 186: Kaio Therapy Raises USD0.2 Million in Venture Financing 301
- Table 187: Credence MedSystems Raises USD15 Million in Series A Financing 302
- Table 188: Chrono Therapeutics Raises USD47.6 Million in Series B Financing 303
- Table 189: Enable Injections Raises USD10 Million in Venture Financing 305
- Table 190: Fe3 Medical Raises Additional USD3.5 Million in Series B Financing Round 306
- 1.2 List of Figures
- Figure 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023 35
- Figure 2: Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016 37
- Figure 3: Drug Delivery Devices Market, United States, Category Contribution (%), 2016 38
- Figure 4: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 39
- Figure 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 41
- Figure 6: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 43
- Figure 7: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 45
- Figure 8: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016 47
- Figure 9: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023 49
- Figure 10: Drug Delivery Devices Market, United States, Company Share (%) 2016 51
- Figure 11: Central Venous Catheters Market, United States, Revenue Mix ($m), 2016 53
- Figure 12: Central Venous Catheters Market, United States, Segment Contribution (%), 2016 54
- Figure 13: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 55
- Figure 14: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 57
- Figure 15: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 59
- Figure 16: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 61
- Figure 17: Central Venous Catheters Market, United States, Company Share (%) 2016 64
- Figure 18: Infusion Systems Market, United States, Revenue Mix ($m), 2016 66
- Figure 19: Infusion Systems Market, United States, Segment Contribution (%), 2016 67
- Figure 20: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 68
- Figure 21: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 70
- Figure 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 72
- Figure 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 74
- Figure 24: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 76
- Figure 25: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 78
- Figure 26: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016 80
- Figure 27: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023 82
- Figure 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016 84
- Figure 29: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016 86
- Figure 30: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023 88
- Figure 31: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023 90
- Figure 32: Infusion Systems Market, United States, Company Share (%) 2016 93
- Figure 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 95
- Figure 34: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 96
- Figure 35: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 97
- Figure 36: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 98
- Figure 37: Needle Free Injections Market, United States, Company Share (%) 2016 100
- Figure 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 102
- Figure 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 103
- Figure 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 104
- Figure 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 105
- Figure 42: Metered Dose Inhaler Devices Market, United States, Company Share (%) 2016 107